Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis

References

• American College of Ftheumatology Subcommittee on Rheuma-toid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–46.
   PubMedGoogle Scholar
• Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818–22.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492–8.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthri-tis (in Japanese). Ensho 1996;16:437–58.
   Google Scholar
• Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:411–59.
   Google Scholar
• Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. The population pharmacokinetics of long-term methotrexate in rheu-matoid arthritis. Br J Chin Pharmacol 1998;46:369–76.
   Google Scholar
• Bressolle F, Bologna C, Edno L, Bernard JC, Gomeni R, Sany J, et al. A limited sampling method to estimate methotrexate phar-macokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 1996;49:285–92.
   Google Scholar
• Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, et al. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis. Int J Clin Pharmacol Ther 1998;36:227–30.
   Google Scholar
• Suzuki T, Suzuki Y, Matsuyama T, Ohhashi H, Hashimoto H. Pharmacokinetics after an intermittent low-dose methotrexate treatment in patients with rheumatoid arthritis (in Japanese). Jpn J TDM 1998;4:340–5.
   Google Scholar
• Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS Jr. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Ftheumatol 1989;16:745–8.
   Google Scholar
• Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. J Ftheumatol 1995;22:844–9.
   Google Scholar
• Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual vari-ability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475–7.
   PubMed Web of Science ®Google Scholar
• Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increas-ing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Ftheumatol 1989;16:313–20.
   Google Scholar
• Seideman P. Methotrexate - the relationship between dose and clinical effect. Br J Ftheumatol 1993;32:751–3.
   PubMedGoogle Scholar
• Totokawa S, Furuya T, Nakajima A, Suzuki T, Kashiwazaki S. Effects of low-dose methotrexate therapy in rheumatoid arthritis: a comparison of three different dosage regimens (in Japanese). Ryumachi 1997;37:681–7.
   Google Scholar
• Ravelli A, Di Fuccia G, Molinaro M, Ftamenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in chil-dren with juvenile rheumatoid arthritis. J Rheumatol 1993;20: 1573–7.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:677–81.
   PubMedGoogle Scholar
• Yamaoka K, Tanigawara Y. MULTI 2 (BAYES) (in Japanese). In: Hon i R, editor. Population pharmacokinetics nyuumonn (Primer of population pharmacokinetics). 1st ed. Tokyo: Yakugyojihosya; 1988. p. 103–31.
   Google Scholar
• Bressolle F, Kinowski JM, Morel J, Pouly B, Sany J, Combe B. Folic acid alters methotrexate availability in patients with rheuma-toid arthritis. J Ftheumatol 2000;27:2110–4.
   Google Scholar
• Yasuda H. Age-related change in renal function. Differences between the Japanese and the Caucasians in a nomogram and a formula for evaluation of glomerular filtration rate (in Japanese). Med Biol 1980;101:83–6.
   Google Scholar
• Sueyasu M, Mishima K, Shuto H, Hirakawa M, Kataoka Y, Oishi R, et al. Population pharmacokinetic parameters of high-dose methotrexate in osteogenic sarcoma (in Japanese). Jpn J TDM 1997;1:85–6.
   Google Scholar
• Luyckx M, Cazin JL, Burnet C, Gosselin P, Demaille MC. Clinical pharmacokinetics of a 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. Eur J Chin Pharmacol 1985;28: 457–62.
   Google Scholar
• Bokkerink JP, Bakker MA, Hulscher TW, De Abreu RR, Schretlen ED, van Laarhoven JP, et al. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 1986;35: 3549–55.
   Google Scholar
• Bokkerink JP, De Abreu RA, Bakker MA, Hulscher TW, van Baal JM, Schretlen ED, et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988;37:2329–38.
   PubMed Web of Science ®Google Scholar
• Skipper HE, Schabel FM Jr, Menett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetic, phar-macologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431–50.
   PubMedGoogle Scholar
• Fujimoto T. Methotrexate with leucovorin rescue (in Japanese). Igaku no Ayumi 1998;184:440–3.
   Google Scholar
• Takeuchi A, Masuda S, Saito H, Hashimoto Y, Inui K. Trans-stimulation effects of folic acid derivatives on methotrexate trans-port by rat renal organic anion transporter, OAT-K1. J Pharmacol Exp Ther 2000;293: 1034–9.
   Google Scholar
• Home DW, Reed KA. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001;394:39–44.
   Google Scholar
• Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832–5.
   Google Scholar
• Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheu-matoid arthritis and psoriatic arthritis patients. Clin Exp Ftheumatol 1995;13:459–63.
   Google Scholar